Comparative Pharmacology
Head-to-head clinical analysis: SODIUM FLUORIDE F 18 versus SODIUM ROSE BENGAL I 131.
Peer-Reviewed Evidence
Head-to-head clinical analysis: SODIUM FLUORIDE F 18 versus SODIUM ROSE BENGAL I 131.
SODIUM FLUORIDE F-18 vs SODIUM ROSE BENGAL I 131
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Positron-emitting radionuclide used for bone imaging; fluoride ion is incorporated into bone matrix via chemisorption onto hydroxyapatite crystals, reflecting blood flow and osteoblastic activity.
Sodium rose bengal I 131 is a radioactive diagnostic agent that is taken up by hepatocytes and excreted into the bile, allowing imaging of the hepatobiliary system. The radioactive iodine (I-131) emits gamma rays, which can be detected externally to assess liver and gallbladder function.
2-10 mCi (74-370 MBq) intravenous bolus injection, single dose for positron emission tomography (PET) bone imaging.
5-50 µCi (0.185-1.85 MBq) intravenous bolus for hepatic function imaging. For functional imaging of hepatobiliary system, typical dose: 150-300 µCi (5.55-11.1 MBq) IV.
None Documented
None Documented
The terminal elimination half-life is approximately 2-4 hours. Clinically, this allows for imaging within 1-3 hours post-injection.
Terminal elimination half-life is approximately 3-7 days, reflecting slow clearance from the liver and bile.
Renal (primarily). Approximately 70% of the administered dose is excreted unchanged in urine within 24 hours. Less than 10% is excreted in feces.
Primarily hepatic excretion into bile (90-95%), with minimal renal excretion (5-10%).
Category C
Category C
Radiopharmaceutical
Radiopharmaceutical